PillRx only · Injection, Suspension, Liposomal · Infiltration
Bupivacaine
Brands: Exparel · Bupivacaine
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
6.1K
Rx · 2026 Q1
90K
Units dispensed
-26%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Pacira Pharmaceuticals, Inc. | unknown | 4 | SUPPLYING |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Nov 21, 2019RECALLRecall (Class II): EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manuf…
Sub Potent Drug: Out of Specification (OOS) — Recalling firm: Pacira Pharmaceuticals, Inc. — Distributed Nationwide in the USA